News - Eli Lilly, Biotechnology


Current filters:

Eli LillyBiotechnology

Popular Filters

1 to 25 of 28 results

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin


The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

Systemic psoriasis market forecast to reach $10.4 billion by 2020


The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint


US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Adocia re-acquires exclusive rights to insulin analog from US drug major


French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report


The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib


Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Turkey's NSCLC drug market forecast to expand at 7% a year through 2017


From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual…

AlimtaBiotechnologyEli LillyEuropeMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV


US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Patient trust in drugmakers declining, new report shows


Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Nexavar use in Chinese patients nearly doubled in 2012


Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada


US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

ASBMR 2012: Anabolics and post-marketing studies


This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial


Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased


US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action


Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

US NIH debuts collaborative program with Pharma to spur therapeutic development


The US National Institutes of Health last week unveiled a collaborative program that will match researchers…

AstraZenecaBiotechnologyEli LillyNorth AmericaPfizerPharmaceuticalResearch

1 to 25 of 28 results

Back to top